Cargando…

iRECIST and atypical patterns of response to immuno-oncology drugs

With the advent of immunotherapy as one of the keystones of the treatment of our patients with cancer, a number of atypical patterns of response to these agents has been identified. These include pseudoprogression, where the tumor initially shows objective growth before decreasing in size, and hyper...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramon-Patino, Jorge Luis, Schmid, Sabine, Lau, Sally, Seymour, Lesley, Gaudreau, Pierre-Olivier, Li, Janice Juan Ning, Bradbury, Penelope Ann, Calvo, Emiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207898/
https://www.ncbi.nlm.nih.gov/pubmed/35715004
http://dx.doi.org/10.1136/jitc-2022-004849
_version_ 1784729625720520704
author Ramon-Patino, Jorge Luis
Schmid, Sabine
Lau, Sally
Seymour, Lesley
Gaudreau, Pierre-Olivier
Li, Janice Juan Ning
Bradbury, Penelope Ann
Calvo, Emiliano
author_facet Ramon-Patino, Jorge Luis
Schmid, Sabine
Lau, Sally
Seymour, Lesley
Gaudreau, Pierre-Olivier
Li, Janice Juan Ning
Bradbury, Penelope Ann
Calvo, Emiliano
author_sort Ramon-Patino, Jorge Luis
collection PubMed
description With the advent of immunotherapy as one of the keystones of the treatment of our patients with cancer, a number of atypical patterns of response to these agents has been identified. These include pseudoprogression, where the tumor initially shows objective growth before decreasing in size, and hyperprogression, hypothesized to be a drug-induced acceleration of the tumor burden. Despite it being >10 years since the first immune-oncology drug was approved, neither the biology behind these paradoxical responses has been well understood, nor their incidence, identification criteria, predictive biomarkers, or clinical impact have been fully described. Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) guidelines have been published as a revision to the RECIST V.1.1 criteria for use in trials of immunotherapeutics, and the iRECIST subcommittee (of the RECIST Working Group) is working on elucidating these aspects, with data sharing a current major challenge to move forward with this unmet need in immuno-oncology.
format Online
Article
Text
id pubmed-9207898
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-92078982022-06-29 iRECIST and atypical patterns of response to immuno-oncology drugs Ramon-Patino, Jorge Luis Schmid, Sabine Lau, Sally Seymour, Lesley Gaudreau, Pierre-Olivier Li, Janice Juan Ning Bradbury, Penelope Ann Calvo, Emiliano J Immunother Cancer Review With the advent of immunotherapy as one of the keystones of the treatment of our patients with cancer, a number of atypical patterns of response to these agents has been identified. These include pseudoprogression, where the tumor initially shows objective growth before decreasing in size, and hyperprogression, hypothesized to be a drug-induced acceleration of the tumor burden. Despite it being >10 years since the first immune-oncology drug was approved, neither the biology behind these paradoxical responses has been well understood, nor their incidence, identification criteria, predictive biomarkers, or clinical impact have been fully described. Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) guidelines have been published as a revision to the RECIST V.1.1 criteria for use in trials of immunotherapeutics, and the iRECIST subcommittee (of the RECIST Working Group) is working on elucidating these aspects, with data sharing a current major challenge to move forward with this unmet need in immuno-oncology. BMJ Publishing Group 2022-06-16 /pmc/articles/PMC9207898/ /pubmed/35715004 http://dx.doi.org/10.1136/jitc-2022-004849 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Ramon-Patino, Jorge Luis
Schmid, Sabine
Lau, Sally
Seymour, Lesley
Gaudreau, Pierre-Olivier
Li, Janice Juan Ning
Bradbury, Penelope Ann
Calvo, Emiliano
iRECIST and atypical patterns of response to immuno-oncology drugs
title iRECIST and atypical patterns of response to immuno-oncology drugs
title_full iRECIST and atypical patterns of response to immuno-oncology drugs
title_fullStr iRECIST and atypical patterns of response to immuno-oncology drugs
title_full_unstemmed iRECIST and atypical patterns of response to immuno-oncology drugs
title_short iRECIST and atypical patterns of response to immuno-oncology drugs
title_sort irecist and atypical patterns of response to immuno-oncology drugs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207898/
https://www.ncbi.nlm.nih.gov/pubmed/35715004
http://dx.doi.org/10.1136/jitc-2022-004849
work_keys_str_mv AT ramonpatinojorgeluis irecistandatypicalpatternsofresponsetoimmunooncologydrugs
AT schmidsabine irecistandatypicalpatternsofresponsetoimmunooncologydrugs
AT lausally irecistandatypicalpatternsofresponsetoimmunooncologydrugs
AT seymourlesley irecistandatypicalpatternsofresponsetoimmunooncologydrugs
AT gaudreaupierreolivier irecistandatypicalpatternsofresponsetoimmunooncologydrugs
AT lijanicejuanning irecistandatypicalpatternsofresponsetoimmunooncologydrugs
AT bradburypenelopeann irecistandatypicalpatternsofresponsetoimmunooncologydrugs
AT calvoemiliano irecistandatypicalpatternsofresponsetoimmunooncologydrugs